Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Multiple Myeloma, Triple Negative Breast...
Phase PHASE1
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose modifications and avoid neutropenic fever (fever in the setting of low neutrophils) for people with Duffy null phenotype receiving treatment for multiple myeloma or triple negative breast cancer. The observational study is to collect dose modification and neutropenic fever information on patients who do not have the Duffy null phenotype and receive the same standard of care regimens to see if there are differences in dose modifications and neutropenic fever between the two groups. The survey studies seek to understand general health experiences and preferences and experiences specific to people with Duffy null phenotype. Study Drugs Include: * Daratumumab * lenalidomide * bortezomib * dexamethasone * carboplatin * paclitaxel * pembrolizumab * cyclophosphamide * doxorubicin

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dexamethasone — Tablet, taken orally
  • Drug: Bortezomib — Intravenous infusion
  • Drug: LENALIDOMIDE — Tablet, taken orally
  • Drug: Daratumumab — Intravenous infusion
  • Drug: Carboplatin — Intravenous infusion
  • Drug: Paclitaxel — Intravenous infusion
  • Drug: Pembrolizumab — Intravenous infusion
  • Drug: Cyclophosphamide — Intravenous infusion

Primary Outcomes

  • Avoided or reduced systemic anticancer therapy (SACT) modifications per cycle (Avoided or reduced modifications determined by ANC (anticancer therapy) values in each treatment cycle. Coh 1 (Dara-RVD) is 6 cycles(cycle=28 dys)-ANC assessed days 1, 8, 15, & 22. Coh 2 has 8 cycles (cycle=21 dys)-ANC assessed days 1, 8, & 15)
  • Overall cumulative incidence of neutropenic fever (Neutropenic fever is assessed from treatment initiation through the end of protocol-based treatment. It will be assessed at baseline and before treatment dosing during each cycle (Coh1 is 6 cycles (cycle=28 days); Coh 2 is 8 cycles (cycle=21 days)).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-07-30
Completion: 2029-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Andrew Hantel, MD
Principal Investigators:
  • Andrew Hantel, MD (PRINCIPAL_INVESTIGATOR) - MD
Contact Information
Study Contact:
Andrew Hantel, MD
617-582-9394
andrew_hantel@dfci.harvard.edu
Andrew Hantel, MD
617-582-9394
Andrew_hantel@dfci.harvard.edu
Dana-Farber Cancer Institute
Andrew Hantel, MD
Dana-Farber Cancer Institute
Interventions
  • Drug: Dexamethasone — Tablet, taken orally
  • Drug: Bortezomib — Intravenous infusion
  • Drug: LENALIDOMIDE — Tablet, taken orally
  • Drug: Daratumumab — Intravenous infusion
  • Drug: Carboplatin — Intravenous infusion
Study Locations (2 sites)
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
The Christ Hospital Cancer Center-Research, Cincinnati, Ohio 45219 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of: * Cohort 1: MM, based on IMWG criteria12, and currently requires treatment * Cohort 2: Stage II or III TNBC, with definition per protocol Section 3.2.1 AND * Plan for treatment, per their treating physician, or currently receiving their first cycle (see 3.3.3 for definition) of: * Cohort 1: Dara-RVd for MM * Cohort 2: A Keynote 522-based regimen of carboplatin, paclitaxel, and pembrolizumab given as the first phase of neoadjuvant treatment for TNBC.\*\*\* * Participants are eligible even if the duration of carboplatin and paclitaxel goes beyond 4 cycles, or if the use of pembrolizumab, doxorubicin, and cyclophosphamide is not planned or is not certain, as long as neoadjuvant treatment starts with carboplatin-paclitaxel-pembrolizumab. This cohort will be referred to as "Keynote 522" for the remainder of the protocol. AND * Confirmed Duffy null phenotype * Previous testing is acceptable if performed by a CLIA-approved test AND * Age \>=18 years old Exclusion Criteria: * Inability to understand and the willingness to sign a written informed consent document * ANC\<500 within 7 days of planned start of Cycle 1 Day 1. * Participants who have started treatment at the time of enrollment cannot have started Cycle 2 of therapy * Participants in Cohort 2 (TNBC) cannot have received any of the pembrolizumab, doxorubicin, and cyclophosphamide portion of therapy * Participants receiving any other investigational agents for any indication * Another known condition or medicine with known impacts on neutrophil counts or neutrophil function
Conditions Breast Cancer
Phase PHASE3
Enrollment 250
Locations 88 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Deruxtecan — Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug

Primary Outcomes

  • Time From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT) (Until subsequent therapy or death, assessed up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-12-30
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daiichi Sankyo
Collaborators: AstraZeneca
Principal Investigators:
  • Global Clinical Leader (STUDY_DIRECTOR) - Daiichi Sankyo
Contact Information
Study Contact:
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
908-992-6400
CTRinfo@dsi.com
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information
+81-3-6225-1111 (M-F 9-5 JST)
dsclinicaltrial@daiichisankyo.co.jp
Study Coordinator
Dana-Farber Cancer Institute
Interventions
  • Drug: Trastuzumab Deruxtecan — Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Study Locations (88 sites)
Mount Sinai Medical Center, Miami Beach, Florida 33140 United States
USF College of Medicine, Tampa, Florida 33602 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
Beth Israel Lahey Health, Burlington, Massachusetts 01805 United States
Overlook Medical Center, Summit, New Jersey 07901 United States
Mater Hospital Sydney, North Sydney, New South Wales 2065 Australia
Monash Medical Centre Moorabbin, East Bentleigh, Victoria 3165 Australia
GenesisCare St Andrews Hospital, Adelaide, 5000 Australia
Fiona Stanley Hospital, Murdoch, 6150 Australia
Institut Jules Bordet, Anderlecht, 1070 Belgium
Eligibility Criteria
Inclusion Criteria: * Sign and date the main informed consent form * Must agree to provide a newly obtained or archival baseline biopsy from primary and/or metastatic lesion. * Pathologically documented Breast Cancer (BC) tumor * Is unresectable and/or metastatic. * Is hormone receptor-negative or hormone receptor-positive. * Must include percentage of positively stained cells to characterize if hormone receptor-positive or -negative. * Has confirmed HER2 IHC 1+ or IHC 2+/ISH- (HER2-low) status or HER2 IHC 0 status as determined according to ASCO CAP 2018 guidelines1 based on sample collected during Tissue Screening as described above. * Was never previously HER2-positive (IHC 3+ or IHC 2+/ISH+) on prior pathology testing (per ASCO CAP guidelines). * Was never previously treated with anti-HER2 therapy in the metastatic setting. * Has had at least one and up to two prior lines of therapy in the metastatic setting. * In participants with hormone receptor-positive HER2-low metastatic BC (Cohort 3): * Has recurrent disease \<2 years from the initiation of adjuvant ET OR * Has disease progression on CDK4/6 inhibitor-based regimen within 12 months of completion of adjuvant therapy with a CDK4/6 inhibitor OR * Has disease progression within the first 12 months of CDK4/6 in the first line metastatic setting * Presence of at least one measurable lesion based on computed tomography or magnetic resonance imaging. * Participants with brain metastases are allowed in the study. The brain lesion(s) should be small (\<2 cm), untreated, asymptomatic, not requiring urgent medical intervention, and are asymptomatic and clinically stable. * Has an Eastern Cooperative Oncology Group performance status of 0 or 1. * Has a minimum life expectancy of 12 weeks at Screening. * Has a left ventricular ejection fraction ≥50% within 28 days before enrollment. * Has adequate organ and bone marrow function within 28 days before enrollment. * Has adequate treatment washout period before enrollment. * Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception. Exclusion Criteria: * Prior treatment with an antibody drug conjugate (ADC). * Uncontrolled or significant cardiovascular disease. * Has a corrected QT interval prolongation. * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening. * Has spinal cord compression or clinically active central nervous system metastases. * Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, other solid tumors curatively treated, or contralateral BC. * Has a history of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product. * Has a history of severe hypersensitivity reactions to other monoclonal antibodies. * Has an uncontrolled infection requiring intravenous (IV) antibiotics, antivirals, or antifungals. * Active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. * Has history of receiving a live, attenuated vaccine (messenger RNA and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study drug. * Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline. * Is pregnant or breastfeeding or planning to become pregnant. * Lung-specific intercurrent clinically significant illnesses. * Any autoimmune, connective tissue, or inflammatory disorders. * Prior complete pneumonectomy.
Conditions HR+/HER2- Breast Cancer
Phase PHASE3
Enrollment 1056
Locations 241 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BGB-43395 — Administered orally.
  • Drug: Letrozole — Administered orally.
  • Drug: Abemaciclib — Administered orally.
  • Drug: Palbociclib — Administered orally.
  • Drug: Ribociclib — Administered orally.

Primary Outcomes

  • Progression-Free Survival (PFS) Determined by Blinded Independent Central Review (BICR) (Up to approximately 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-22
Completion: 2037-08-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1056 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BeOne Medicines
Principal Investigators:
  • Study Director (STUDY_DIRECTOR) - BeOne Medicines
Contact Information
Study Contact:
Study Director
877-828-5568
clinicaltrials@beonemed.com
Interventions
  • Drug: BGB-43395 — Administered orally.
  • Drug: Letrozole — Administered orally.
  • Drug: Abemaciclib — Administered orally.
  • Drug: Palbociclib — Administered orally.
  • Drug: Ribociclib — Administered orally.
Study Locations (241 sites)
Alabama Oncology Princeton, Birmingham, Alabama 35211 United States
Alaska Oncology and Hematology, Llc, Anchorage, Alaska 99508-2974 United States
Fairbanks Cancer Care Physicians Pc, Fairbanks, Alaska 99701 United States
Pioneer Research Center, Bullhead City, Arizona 86442 United States
Ironwood Cancer and Research Centers Chandler Ii, Chandler, Arizona 85224-5665 United States
City of Hope Phoenix Cancer Center, Goodyear, Arizona 85338 United States
Genesis Cancer and Blood Institute Hot Springs (Harmony Park), Hot Springs, Arkansas 71913 United States
City of Hope National Medical Center, Duarte, California 91010-3012 United States
Helios Clinical Research the Oncology Institute Fountain Valley, Fountain Valley, California 92708 United States
California Research Institute, Los Angeles, California 90027 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent. * Participants with histologically confirmed locally advanced or metastatic HR+ HER2- breast cancer. * Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1. * Adequate organ function. Exclusion Criteria: * Participants who have received prior systemic treatment in the advanced or metastatic setting. * Participants who have received prior treatment with any selective cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 2 (CDK2) targeting agent, or any other investigational anticancer drug in any disease setting, except for prior investigational or approved SERDs in the adjuvant setting, provided that disease recurrence occurred more than 12 months after the last dose of endocrine-based therapy. * Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Conditions HER2-low Breast Cancer
Phase PHASE3
Enrollment 566
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-M07D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel — Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.

Primary Outcomes

  • Progression-free survival (PFS) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-05-15
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 566 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Herui Yao
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Quchang Ouyang
Hunan Cancer Hospital
Interventions
  • Drug: BL-M07D1 — Administration by intravenous infusion for a cycle of 3 weeks.
  • Drug: Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel — Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
Study Locations (2 sites)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong China
Hunan Cancer Hospital, Changsha, Hunan China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent and follow the requirements of the protocol; 2. Women aged ≥18 years and ≤75 years at the time of written informed consent; 3. Expected survival time ≥12 weeks; 4. Histologically or cytologically confirmed unresectable, locally recurrent or metastatic HER2-low breast cancer; 5. Provide the latest tumor tissues to the central laboratory for HER2 and HR detection; 6. Meet the treatment requirements in the plan; 7. Must have at least one measurable target lesion that meets the RECIST v1.1 definition; 8. ECOG 0 or 1; 9. Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0; 10. Organ function level must meet the requirements; 11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) should use adequate, highly effective contraception for the entire treatment cycle and for 7 months after completion of treatment. Exclusion Criteria: 1. Received mitomycin C and nitrosourea chemotherapy within 6 weeks before the first dose, and received surgery or radical radiotherapy within 4 weeks before the first dose; 2. Patients who were not suitable to use the control drugs chosen by the researchers because of intolerance to the chemotherapy drugs of the control group or other contraindications; 3. Previous treatment with anti-HER2 drugs; 4. Prior ADC drug therapy with camptothecin derivative as toxin; 5. The history of severe cardiovascular and cerebrovascular diseases in the past six months was screened; 6. Severe impairment of lung function due to concurrent pulmonary diseases; 7. History of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia or suspected ILD/interstitial pneumonia; 8. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia; 9. Other primary malignancies diagnosed within 5 years before the first dose; 10. Poorly controlled hypertension; 11. Patients with active central nervous system metastases; 12. Patients with a history of severe allergy to any excipients or components of the study drug; 13. History of autologous or allogeneic stem cell transplantation or organ transplantation; 14. Anthracycline-equivalent cumulative dose of adriamycin \> 360 mg/m2; 15. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection; 16. Serious infection within 4 weeks before the first dose of study drug; Severe infection requiring antibiotic, antiviral or antifungal control at screening; 17. Patients with massive effusions, or effusions with obvious symptoms, or poorly controlled effusions; 18. Carcinomatous lymphangitis; 19. Was receiving \&gt before randomization; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy; 20. The presence of a severe neurological or mental illness; 21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent; 22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea; 23. Subjects who are scheduled to receive live vaccine or receive live vaccine within 28 days before the first dose; 24. Patients with other serious physical or laboratory abnormalities or poor compliance that may increase the risk of participating in the study or interfere with the results of the study, and patients who are considered by the investigators to be unsuitable for participating in the study.
Conditions Triple Negative Breast Cancer
Phase NA
Enrollment 60
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Prospective multicenter study evaluating the prediction of histological response after neoadjuvant pembrolizumab in combination with chemotherapy by pre-treatment 68Ga-FAPI-46 PET/CT imaging in patients with early-stage high-risk TNBC.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: 68Ga-FAPI-46 PET/CT imaging — The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.

Primary Outcomes

  • Area under the ROC curve (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-14
Completion: 2032-11-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Curie
Principal Investigators:
  • Romain-David SEBAN (PRINCIPAL_INVESTIGATOR) - Institut Curie
Contact Information
Study Contact:
Sandra Nespoulous
0147111654
drci.promotion@curie.fr
Marie-Emmanuelle LEGRIER
0156245649
drci.promotion@curie.fr
Amal GHOUADNI, MD
Hôpital Privé d'Antony
Interventions
  • Procedure: 68Ga-FAPI-46 PET/CT imaging — The 68Ga-FAPI-46 PET/CT scan will be performed for each patient pre-therapy and on the same machine as the 18F-FDG PET/CT scan and within 14 days before the start of treatment.
Study Locations (6 sites)
Hôpital Privé d'Antony, Antony, 92160 France
Institut Curie -site Paris, Paris, 75005 France
GH Diaconesses Croix Saint-Simon, Paris, 75020 France
Institut Curie -site St Cloud, Saint-Cloud, 92210 France
HIA Begin, Saint-Mandé, 94160 France
Hôpital FOCH, Suresnes, 92150 France
Eligibility Criteria
Inclusion Criteria: 1. Female with age ≥ 18 years, 2. Patients with previously untreated, non-metastatic, centrally confirmed TNBC for whom a neoadjuvant treatment with chemotherapy + pembrolizumab is the recommended option as standard of care, 3. Patients with measurable targets according to RECIST/PERCIST criteria, 4. Patients without distant metastasis based on staging 18F-FDG PET/CT, 5. Patients with tumor tissue available, 6. Patients who provided a signed written informed consent, 7. Patient ability to comply with protocol requirements, 8. Patients covered by a health insurance system. Exclusion Criteria: 1. Pregnant and lactating women, 2. Patients with prior anti-PD(L)1 immunotherapy, 3. Patients with any contra-indication to chemo-immunotherapy standard of care therapy, per investigator assessment, 4. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent, 5. Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons, 6. Person deprived of liberty or under guardianship
Conditions Breast Cancer
Phase Not Applicable
Enrollment 104
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Breast-conserving surgery (lumpectomy) aims to remove cancer while preserving healthy tissue, but up to 20% of patients require a second operation because cancer cells remain at the edge (margin) of the removed tissue. The Spectra-BREAST study evaluates a new optical device that combines hyperspectral imaging (HIS) and Raman spectroscopy (RS) with artificial-intelligence analysis to quickly assess the entire surface of excised breast specimens during surgery. By flagging areas at risk of positive margins in real time, the device may help surgeons remove any remaining cancer in a single procedure. In this prospective, single-arm diagnostic study, surgeons will use the Spectra-BREAST system on freshly resected breast tissue from up to 99 women undergoing lumpectomy for invasive carcinoma or ductal carcinoma in situ. First, the device's cancer-detection algorithms will be trained on 74 specimens with known pathology. Then, in a separate group of patients, the fully integrated device will be tested on all six faces of each lumpectomy specimen and its predictions will be compared against the gold-standard histopathology margin assessment. Key measures include the sensitivity and specificity of the device's margin predictions, the time needed to generate results, and the device's usability in a clinical setting.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Spectra-BREAST system in Invasive Breast Cancer — Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected "hotspots" flagged by HSI as at risk. RS will be acquired on the surface of the specimens confirming the possible presence of positive margins Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed.
  • Diagnostic Test: Spectra-BREAST system in DCIS Breast Cancer — Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected "hotspots" flagged by HSI as at risk. RS will be acquired on the surface of the specimens and using a special needle probe 2 mm below the tissue surface thus confirming the possible presence of positive margins. Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed

Primary Outcomes

  • Sensitivity and specificity of Spectra-BREAST system margin status prediction (Within 21 days after surgery (latest expected receipt of the final pathology report).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-06
Completion: 2028-12
Eligibility
Age: 18 Years – 85 Years
Sex: FEMALE
Volunteers: false
Enrollment: 104 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istituti Clinici Scientifici Maugeri SpA
Principal Investigators:
  • Carlo F Morasso, Ph.D. (PRINCIPAL_INVESTIGATOR) - Istituti Clinici Scientifici Maugeri
Contact Information
Study Contact:
Fabio Corsi, Prof.
+390382592219
fabio.corsi@icsmaugeri.it
Interventions
  • Diagnostic Test: Spectra-BREAST system in Invasive Breast Cancer — Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected "hotspots" flagged by HSI as at risk. RS will be acquired on the surface of the specimens confirming the possible presence of positive margins Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed.
  • Diagnostic Test: Spectra-BREAST system in DCIS Breast Cancer — Participants' excised breast lumpectomy specimens will be immediately imaged ex vivo using the investigational Spectra-BREAST system, a handheld optical device integrating two modalities Hyperspectral imaging (HSI): HSI captures reflectance spectra across 400-1400 nm over the entire specimen surface (up to 5 × 5 cm field of view). HIS provides spatial maps of tissue chemical composition and morphology to highlight regions suspicious for residual carcinoma. Point-wise Raman spectroscopy (RS): RS will allow to acquire high-resolution molecular fingerprints both at high and low Raman shift on selected "hotspots" flagged by HSI as at risk. RS will be acquired on the surface of the specimens and using a special needle probe 2 mm below the tissue surface thus confirming the possible presence of positive margins. Spectra-BREAST system will allow to provide a near real time feedback to the surgeon on the presence and position of positive margins allowing a further resection if tissue if needed
Study Locations (1 sites)
Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Lombardy 27100 Italy
Eligibility Criteria
Inclusion Criteria: Histologically confirmed diagnosis of ductal carcinoma in situ (B5a) or invasive breast carcinoma (B5b) on pre-operative core needle biopsy Scheduled to undergo breast-conserving surgery (lumpectomy) Able and willing to provide written informed consent Exclusion Criteria: Pre-operative histologic or cytologic diagnosis of a benign breast lesion (B2/C2) Initial diagnosis of advanced (stage III/IV) or metastatic breast carcinoma, or indication for neoadjuvant chemotherapy Neurocognitive disorders that would impair comprehension of the study procedures or consent process Concurrent pregnancy or breastfeeding
Conditions Breast Cancer, Breast Neoplasms, Breast ...
Phase PHASE2
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tirzepatide — Patients will receive tirzepatide once weekly for up to 2 years.

Primary Outcomes

  • ctDNA efficacy (2 years)
  • distant disease-free survival efficacy (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-11-26
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Baylor Research Institute
Principal Investigators:
  • Joyce A O'Shaughnessy, MD (PRINCIPAL_INVESTIGATOR) - Baylor Scott & White The Heart Hospital
Contact Information
Study Contact:
CORC Solid Tumor
214-818-8472
corcsolidtumor@bswhealth.org
Page E Blas, MA
214-820-5424
page.blas@bswhealth.org
Page E Blas, MA
214-820-5424
page.blas@bswhealth.org
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
Interventions
  • Drug: Tirzepatide — Patients will receive tirzepatide once weekly for up to 2 years.
Study Locations (1 sites)
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas 75246 United States
Eligibility Criteria
Inclusion Criteria: 1. Female or male patients ≥18 years of age 2. Have a diagnosis of node-positive, hormone receptor-positive (ER+ \> 10%), and HER2-negative breast cancer within the past 15 years per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines 1. If patients have synchronous bilateral ER+ breast cancers, tissue from both primary cancers should be submitted for next-generation sequencing (NGS) to inform ctDNA testing 2. Patients with multifocal/multicentric cancers are eligible and the largest focus of cancer should be submitted for NGS evaluation. If tested, all tumor foci must meet have ER \> 10% 3. For patients who received neoadjuvant therapy and have discordant hormone receptor and/or HER2 results between the diagnostic biopsy (pre-treatment) and the surgical pathology (post-neoadjuvant treatment), the hormone receptor status and HER2 status of the post-treatment specimen will determine eligibility 3. Overweight or obesity defined as body mass index (BMI) \> 27 kg/m2 4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 5. Have received at least 1 year of or having completed standard neo/adjuvant endocrine therapy. If adjuvant cyclin dependent kinase (CDK) 4/6 inhibitor therapy was prescribed, patients must have completed this therapy 6. Positive ctDNA blood test as determined by the Haystack Oncology Haystack MRD tumor-informed ctDNA assay 7. Patients must have formalin-fixed paraffin-embedded (FFPE) tissue from the primary tumor available for submission to Haystack Oncology to perform whole genome sequencing (WGS) to build customized mutation panel to monitor for plasma ctDNA 8. No clinical evidence of metastatic breast cancer found on history, physical examination, complete blood count (CBC), comprehensive metabolic panel (CMP), and radiologic imaging following a finding of positive ctDNA 9. Have adequate hematologic function, defined by: 1. Absolute neutrophil count (ANC) \>1500/µL 2. Platelet count ≥100,000/ µL 3. Hemoglobin ≥9 g/dL or ≥5.6 mmol/L 10. Have adequate liver function, defined by: 1. Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤3 x the upper limit of normal (ULN) 2. Total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ULN for patients with total bilirubin levels \>1.5 × ULN 11. Have adequate renal function, defined by: a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥30 mL/min 12. Patients must be accessible for treatment and follow-up 13. All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry Exclusion Criteria: 1. Prior bariatric surgery and/or endoscopic procedures for weight loss (e.g., intragastric balloon, sleeve gastrostomy) following diagnosis of breast cancer 2. Treatment with a GLP-1/Glucagon receptor agonist, GIP/GLP-1/Glucagon receptor agonist, GIP/GLP receptor agonist, or any combinations with GLP-1 receptor agonist therapies within the last 3 months 3. History of severe hypersensitivity reaction to GLP-1/Glucagon receptor agonist, GIP/GLP-1/Glucagon receptor agonist, or any combinations with GLP-1 receptor agonist therapies 4. Insulin-dependent diabetes 5. Has clinical evidence of diabetic retinopathy 6. Clinical evidence or suspicion of metastatic breast cancer 7. Current or past invasive cancers, other than breast cancer, are not allowed except for: 1. Adequately treated basal or squamous cell carcinoma of the skin 2. Previously diagnosed invasive cancer treated with curative intent, with no evidence of disease recurrence for at least 5 years, and are considered low risk for future recurrence by the treating physician 8. Patients with a second synchronous primary HER2-positive or triple negative breast cancer 9. Has an active infection requiring systemic therapy 10. Has a known history of human immunodeficiency virus (HIV) or active or persistent hepatitis B or hepatitis C virus 11. Has significant cardiovascular disease, such as: 1. History of stroke, myocardial infarction, acute coronary syndrome, or coronary angioplasty/stenting/bypass grafting within the last 6 months 2. Congestive heart failure (CHF) New York Heart Association (NYHA) Class II-IV, or history of CHF NYHA class III or IV. 12. Has a known history of active tuberculosis 13. Women who are pregnant or lactating. All patients of reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug 14. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: 1. severe impaired lung functions as defined as spirometry and diffusing capacity of lung for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air 2. liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C) 3. history of gastroparesis, impaired gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of the study drug (e.g., ulcerative diseases, uncontrolled nausea vomiting and/or diarrhea, malabsorption syndrome, or small bowel resection) 15. Has a history of pancreatitis or current symptoms of untreated cholelithiasis 16. Has a family history of Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) or medullary thyroid cancer (MTC) 17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's full participation for the full duration of the study, or results in trial participation not being in the patient's best interest, in the opinion of the Treating Physician 18. Has received an investigational agent within 4 weeks prior to study treatment; investigational monoclonal antibodies should have a 4-week (28 day) or 5 half-life washout period 19. Any other investigational or anti-cancer treatments while participating in this study with the exception of standard adjuvant endocrine therapy, zoledronic acid, or denosumab
Conditions Breast Cancer, Mastectomy; Lymphedema, Q...
Phase Not Applicable
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This is a response-adaptive (RAR) prospective randomized study with a long-term follow-up and the aim of this clinical study is to measure with qualitative and quantitative indicators the changes in cosmetic results, quality of life and patient satisfaction after delayed- immediate breast reconstruction with standardized technique Skin Reducing Nipple sparing mastectomy, SRNSM and SSM with standardized horizontal skin incision. According to our hypothesis, SRNSM with standardized technique on pendulous/ ptotic breasts is a safe procedure compared to SSM. It also promotes the cosmetic efficacy of SRNSM with the removal of the entire glandular tissue through avoidance of the reduction of projection, the need later nipple reconstruction surgery and of areola tattoo. In our study we propose that compared to one of the well-known and widely investigated studied SSM, our current standardized SRNSM technique is able to perform similar oncologically safe entire gland tissue removal, with low complication rate, accommodating for adjuvant treatments. Furthermore, it may provide superior cosmetic results than SSM (NAC is not removed, projection is maintained, and there is no need for further nipple reconstruction or tattoo) with high patient satisfaction which is maintained long term.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction — Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
  • Procedure: Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery — Classic Skin- Sparing Mastectomy

Primary Outcomes

  • Oncological safety (five years of follow-up)
  • Patients' satisfaction (five years of follow-up)
  • Cosmetic results (five years of follow-up)
  • Quality of life (five years of follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-04-18
Completion: 2027-04-05
Eligibility
Age: 18 Years – 65 Years
Sex: FEMALE
Volunteers: Not specified
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Oncology, Hungary
Contact Information
Study Contact:
Zoltan Matrai, M.D. Dr. med. habil, PhD
+3612248600
matraidoc@gmail.com
National Institute of Oncology
Zoltan Matrai, M.D. Dr. Habil Ph.D. FEBS
National Institute of Oncology
Mihaly Ujhelyi, M.D. Ph.D. FEBS
National Institute of Oncology
Interventions
  • Procedure: Skin Reducing Nipple Sparing Mastectomy and Implant Based Breast Reconstruction — Skin Reducing Nipple Sparing Mastectomy is performed from Inverted T incisuion and nipple is preserved.
  • Procedure: Skin- Sparing Mastectomy and Implant- Based Breast Reconstructive Surgery — Classic Skin- Sparing Mastectomy
Study Locations (1 sites)
National Institute of Oncology, Budapest, 1122 Hungary
Eligibility Criteria
Inclusion Criteria: * Under the age of 65 with uni- or bilateral primary breast cancer ( clinical Stage 0-III), needing skin sparing mastectomy, nipple sparing mastectomy or patients require risk reducing mastectomy independently of the axillary surgery, having immediate or delayed-immediate implant based reconstruction. Exclusion Criteria: * In case the patient does not volunteer for the examination or the follow-ups * Age above 65 years or poor general health condition, where the estimated life expectancies would be less than 2 years even without the tumorous disease * Malignant invasive tumor in the past history (except for non-melanoma skin tumors) * Mastectomy and reconstruction performed due pregnancy associated breast cancer * Prior breast surgery (e.g. aesthetic surgery, mastopexy) and/or radiotherapy on the breast or in the axilla * Malignant tumor is not removed completely with pathological examination * Severe non-surgical (e.g. radiotherapy) complication, which could influence the aesthetic and functional results * Autoimmune diseases * Mastitis carcinomatosa * Lymphangitis carcinomatosa * Open wound therapy due SSI * Long-term steroid usage, which changed the skin's quality and structure * Patient under foster care, or psychically non-cooperative patient
Conditions HER2-positive Breast Cancer, Trastuzumab...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This multi-center observational retrospective study will collect real-world clinical data from eligible patients with unresectable or metastatic HER2+ breast cancer who have received one or more cycles Trastuzumab Deruxtecan in Russian Federation

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. — T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion

Primary Outcomes

  • PFS (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12
Completion: 2026-05
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Blokhin's Russian Cancer Research Center
Principal Investigators:
  • Elena Artamonova (PRINCIPAL_INVESTIGATOR) - The Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health
Contact Information
Study Contact:
Elena Artamonova
+7 (499) 444-24-24
tatiana.titovadoc@gmail.com
Elena А Artamonova
4994442424
tatiana.titovadoc@gmail.com
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation
Interventions
  • Drug: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. — T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days. Intravenous infusion
Study Locations (1 sites)
Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" оf the Ministry of Health of the Russian Federation, Moscow, 115522 Russia
Eligibility Criteria
Inclusion Criteria: 1. Patients aged over 18 years old. 2. Metastatic breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 3. Patients has received Trastuzumab Deruxtecan 4. Available medical history. Exclusion Criteria: 1. Incomplete medical history. 2. Pregnancy or breast-breeding
Conditions Sensation Disorders, Sensation, Phantom,...
Phase Not Applicable
Enrollment 400
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

During breast surgery, sensory nerves are cut which may lead to reduced sensation and pain. Surgical reinnervation techniques have been developed with the aim of improving postoperative sensation by preserving the nerves and connecting them to the nipple and areola. The investigators aim to compare postoperative sensation and patient reported outcomes in patients undergoing reinnervation versus those not undergoing reinnervation to determine if there is a difference. The investigators will investigate this in patients undergoing gender-affirming mastectomy, implant-based breast reconstruction and autologous breast reconstruction. The investigators will use various tools that measure sensation quantitatively.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Sensory testing — Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)

Primary Outcomes

  • Change in Breast Q scores (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in Gender-Q scores (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in cold detection threshold (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in warm detection threshold (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in heat pain threshold (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in mechanical detection threshold (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in two-point discrimination (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
  • Change in mechanical pain threshold (preoperative, postoperative at 1 month, 3 months, 6 months, and 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-02-09
Completion: 2033-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Massachusetts General Hospital
Principal Investigators:
  • Lisa Gfrerer, MD, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Lisa Gfrerer, MD, PhD
646.962.4250
lig4013@med.cornell.edu
Lisa Gfrerer, MD. PhD
(646) 962-2330
lgfrerer@partners.org
Massachusetts General Hospital
Lisa Gfrerer, MD, PhD
Massachusetts General Hospital
Interventions
  • Diagnostic Test: Sensory testing — Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
Study Locations (2 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: * Age over 18 * Patient is scheduled for gender mastectomy surgery (including nipple sparing mastectomy and mastectomy with free nipple graft) or NSM with breast implant or autologous reconstruction * Patient is capable and willing to provide informed consent Exclusion Criteria: * Patient has a nerve condition that does not allow for assessment of sensation * Any subject who at the discretion of the Investigator is not suitable for inclusion in the study or is unlikely to comply with follow-up schedule * Currently prescribed medication known to impact nerve regeneration or to cause peripheral neuropathy * Bilateral reconstruction with non-uniform treatment (i.e. 1 reconstructed breast is non-neurotized, 1 reconstructed breast is neurotized)
Conditions HIV-1-infection, Coronary Microvascular ...
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Health Education — Health Education
  • Other: Subspecialty clinic referral — This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.

Primary Outcomes

  • Coronary Flow Reserve (24 weeks)
  • Ectopic Adipose Tissue (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-17
Completion: 2029-06
Eligibility
Age: 45 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Markella V Zanni, MD (PRINCIPAL_INVESTIGATOR) - MGH/HMS
Contact Information
Study Contact:
Sarah Chu, NP
617-724-6091
schu4@mgh.harvard.edu
Markella Zanni, MD
Massachusetts General Hospital
Interventions
  • Other: Health Education — Health Education
  • Other: Subspecialty clinic referral — This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * female sex-at-birth * self-report of HIV on stable antiretroviral therapy ≥180 days * age 45 -75 years * at least 1 of the following 3 conditions: i) type 2 diabetes mellitus ii) estimated glomerular filtration rate 30-60 ml/min/1.73 m2 iii) urine albumin to creatinine ratio \>30 mg/g * coronary flow reserve \<2.5 or stress myocardial blood flow \<2.5 on screening cardiac positron emission tomography/computed tomography Exclusion Criteria: * current SGLT2 inhibitor use * known allergy to SGLT2 inhibitor use * type 1 diabetes or ketoacidosis prone diabetes (diabetes with a history of ketoacidosis) * self-reported history of polycystic kidney disease * self-reported history of myocardial infarction, stroke, or coronary revascularization * stable or unstable angina * self-reported history of heart failure * hemoglobin A1c ≥8.5% at screen * uncontrolled hypertension at screen, defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg * estimated glomerular filtration rate \<30 ml/min/1.73 m2 * currently receiving hemodialysis or peritoneal dialysis * CD4 \<400 cell/mm3 * current treatment with systemic (oral, IV, IM or intra-articular) steroids or anti-inflammatory/immune suppressant therapies (excluding topical therapies, UV therapy, ASA-derivatives, or NSAIDs) for any indication, including kidney disease * pregnancy or breastfeeding * known allergy to 13N Ammonia/82Rubidium or to Regadenoson/Adenosine * concurrent enrollment in conflicting research study * self-reported history of recurrent urinary tract-infections (≥2 urinary tract infections within 6 months or ≥3 within a year) and/or recurrent vaginal yeast infections (≥2 vaginal yeast infections within 6 months or ≥3 within a year) * currently receiving 24-hour-a-day home oxygen therapy
Conditions Type 2 Diabetes (T2DM)
Phase PHASE3
Enrollment 350
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GZR33 Injection — GZR33 Injection Administered SC, once-daily
  • Drug: Insulin Degludec Injection (Tresiba®) — Administered SC, once-daily

Primary Outcomes

  • Change in Hemoglobin A1c (HbA1c) from baseline after 26 weeks of treatment. (Baseline , 26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-04-07
Completion: 2027-04-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gan & Lee Pharmaceuticals.
Contact Information
Study Contact:
Yuchi Liu
010-8059-5000
yuchi.liu@ganlee.com
Interventions
  • Drug: GZR33 Injection — GZR33 Injection Administered SC, once-daily
  • Drug: Insulin Degludec Injection (Tresiba®) — Administered SC, once-daily
Study Locations (1 sites)
Gan & Lee Pharmaceuticals, Beijing, China
Eligibility Criteria
Inclusion Criteria: 1. Subjects sign the Informed Consent Form (ICF) before the study, fully understand the contents, process and possible adverse reactions of the study, and are able to follow the contraindications and restrictions specified in this protocol. 2. Male or female, aged ≥18 years at the time of informed consent.. 3. Body mass index (BMI) ≥18.5 and ≤35.0 kg/m2 at screening. 4. According to the diagnostic criteria and classification of diabetes mellitus issued by the World Health Organization (WHO) in 1999, and the supplementary diagnostic criteria recommended by WHO for diagnosis with Hemoglobin A1c (HbA1c) (2011), the time to diagnose T2DM is ≥ 180 days at screening. 5. Stable treatment with oral antidiabetic drugs for ≥ 90 days prior to screening. Exclusion Criteria: 1. History of hypersensitivity to ≥ 2 drugs with distinct mechanisms of action, or known hypersensitivity, allergic reactions, or intolerance to the investigational medicinal products or their excipients (glycerol, phenol, metacresol, zinc acetate dihydrate, sodium chloride, hydrochloric acid, sodium hydroxide). 2. Female subjects who are pregnant, lactating at screening, or planning a pregnancy during the trial period. 3. Confirmed or suspected type 1 diabetes mellitus or specific types of diabetes due to other causes (monogenic diabetes syndrome, cystic fibrosis-related diabetes, pancreatitis-induced diabetes, drug- or chemical-induced diabetes, etc.) prior to screening. 4. Presence of any diseases that may affect HbA1c testing at screening, such as hemolytic anemia, aplastic anemia, hemoglobinopathy, etc., and in the investigator's judgment unsuitable for participation; or blood donation, blood loss \> 400 mL, or blood transfusion within 90 days prior to screening. 5. History of severe cardiovascular and cerebrovascular diseases within 180 days prior to screening. 6. Significant hepatic or renal dysfunction or active infectious diseases at screening. 7. Lifestyle (diet, exercise, work circadian rhythm, etc.) expected to change significantly during the trial and affect glycemic control; irregular three-meal intake (e.g., habitual skipping of breakfast); or unwillingness to comply with relevant lifestyle restrictions during the trial. 8. Any other conditions that, in the investigator's judgment, may compromise subject safety or interfere with trial conduct, progress, or outcome.